Biomark Diagnostics Statistics
Total Valuation
Biomark Diagnostics has a market cap or net worth of CAD 20.39 million. The enterprise value is 21.78 million.
Market Cap | 20.39M |
Enterprise Value | 21.78M |
Important Dates
The last earnings date was Thursday, August 29, 2024.
Earnings Date | Aug 29, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Shares Outstanding | n/a |
Shares Change (YoY) | +5.11% |
Shares Change (QoQ) | +6.63% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 39.12M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 140.09 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -13.35 |
EV / Sales | 131.14 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -20.54 |
Financial Position
The company has a current ratio of 0.14
Current Ratio | 0.14 |
Quick Ratio | 0.14 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -1.41 |
Interest Coverage | -23.07 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -135.65% |
Return on Capital (ROIC) | -175.56% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.19 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.14% in the last 52 weeks. The beta is -0.54, so Biomark Diagnostics's price volatility has been lower than the market average.
Beta (5Y) | -0.54 |
52-Week Price Change | -7.14% |
50-Day Moving Average | 0.24 |
200-Day Moving Average | 0.26 |
Relative Strength Index (RSI) | 62.28 |
Average Volume (20 Days) | 5,205 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biomark Diagnostics had revenue of CAD 161,787 and -1.63 million in losses. Loss per share was -0.02.
Revenue | 161,787 |
Gross Profit | 161,787 |
Operating Income | -1.88M |
Pretax Income | -1.63M |
Net Income | -1.63M |
EBITDA | -1.86M |
EBIT | -1.88M |
Loss Per Share | -0.02 |
Balance Sheet
The company has 141,358 in cash and 1.50 million in debt, giving a net cash position of -1.36 million.
Cash & Cash Equivalents | 141,358 |
Total Debt | 1.50M |
Net Cash | -1.36M |
Net Cash Per Share | n/a |
Equity (Book Value) | -649,612 |
Book Value Per Share | -0.01 |
Working Capital | -1.08M |
Cash Flow
In the last 12 months, operating cash flow was -1.05 million and capital expenditures -6,902, giving a free cash flow of -1.06 million.
Operating Cash Flow | -1.05M |
Capital Expenditures | -6,902 |
Free Cash Flow | -1.06M |
FCF Per Share | n/a |
Margins
Gross Margin | 100.00% |
Operating Margin | -1,159.81% |
Pretax Margin | -1,008.61% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -655.40% |
Dividends & Yields
Biomark Diagnostics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -5.11% |
Shareholder Yield | -5.11% |
Earnings Yield | -7.20% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Biomark Diagnostics has an Altman Z-Score of -19.89. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -19.89 |
Piotroski F-Score | n/a |